title: PGF2alpha-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN.
abstract: Prostaglandin F2alpha (PGF2alpha) increases reactive oxygen species (ROS) and induces vascular smooth muscle cell (VSMC) hypertrophy by largely unknown mechanism(s). To investigate the signaling events governing PGF2alpha-induced VSMC hypertrophy we examined the ability of the PGF2alpha analog, fluprostenol to elicit phosphorylation of Akt, the mammalian target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6k), glycogen synthase kinase-3beta (GSK-3beta), phosphatase and tensin homolog (PTEN), extracellular signal-regulated kinase 1/2 (ERK1/2) and Jun N-terminal kinase (JNK) in growth arrested A7r5 VSMC. Fluprostenol-induced hypertrophy was associated with increased ROS, mTOR translocation from the nucleus to the cytoplasm, along with Akt, mTOR, GSK-3beta, PTEN and ERK1/2 but not JNK phosphorylation. Whereas inhibition of phosphatidylinositol 3-kinase (PI3K) by LY-294002 blocked fluprostenol-induced changes in total protein content, pre-treatment with rapamycin or with the MEK1/2 inhibitor U0126 did not. Taken together, these findings suggest that fluprostenol-induced changes in A7r5 hypertrophy involve mTOR translocation and occur through PI3K-dependent mechanisms.
authors.affiliation: Department of Biological Sciences, Marshall University, Huntington, WV 25755-1090, USA. rice@marshall.edu
authors.forename: K M
authors.initials: KM
authors.lastname: Rice
authors.forename: S
authors.initials: S
authors.lastname: Uddemarri
authors.forename: D H
authors.initials: DH
authors.lastname: Desai
authors.forename: R G
authors.initials: RG
authors.lastname: Morrison
authors.forename: R
authors.initials: R
authors.lastname: Harris
authors.forename: G L
authors.initials: GL
authors.lastname: Wright
authors.forename: E R
authors.initials: ER
authors.lastname: Blough
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002460:Cell Line; D015237:Dinoprost / Q000819:agonists / Q000502:physiology*; D005455:Fluorescent Antibody Technique; D020935:MAP Kinase Signaling System; D008856:Microscopy, Fluorescence; D009131:Muscle, Smooth, Vascular / Q000473:pathology*; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism*; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000037:antagonists & inhibitors / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases
chemical_list: D015237:Dinoprost; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011461:Prostaglandins F, Synthetic; D011494:Protein Kinases; D017382:Reactive Oxygen Species; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases; C006326:fluprostenol; C546843:mTOR protein, mouse; C487757:Pten protein, mouse